Yara reports improved margins in a slow off-season market

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
14
Yara reports improved margins in a slow off-season market

Oslo, 8 February 2019: Net income after non-controlling interests was USD 157 million (USD 0.58 per share), compared with USD 104 million (USD 0.38 per share) a year earlier. Excluding currency effects and special items, the result was USD 0.60 per share compared with USD 0.49 per share in the fourth quarter 2017. Yara's Board of Directors will propose to the Annual General Meeting a dividend payment of NOK 6.50 per share for 2018. Fourth-quarter EBITDA excluding special items was USD 424 million, up 21% compared with a year earlier, reflecting higher production margins, contribution from Yara's growth projects and a stronger US dollar. "Yara shows improved results in fourth quarter with EBITDA excluding special items up 21%. We saw improved margins in a slow off-season market, and the improvement program continued to deliver," said Svein Tore Holsether, President and Chief Executive Officer of Yara. "Following a period of heavy investments, our focus in 2019 is on ramping up our current growth projects, continued operational improvement and maintaining strong capital discipline", said Holsether. Total fertilizer deliveries were 2% higher compared with a year earlier, driven by the Babrala acquisition in India and the Cubatão acquisition in Brazil. Industrial deliveries were 9% higher than a year earlier. Excluding the acquisitions, fertilizer deliveries were down 7% while Industrial deliveries were in line with a year earlier. Yara's ammonia production and finished fertilizer production were both 6% higher. Excluding portfolio effects, ammonia and finished fertilizer production was respectively 11% and 2% lower. The global urea supply-demand balance looks set to remain positive longer term, as nitrogen supply growth is forecast to decline from 2019, and lead times for new projects are typically three to five years. Also, demand growth is likely to pick up since increased grain production is needed to keep pace with consumption and global grain stocks are relatively low, particularly excluding China. The Yara Improvement Program is on track to reach at least USD 500 million of annual EBITDA improvement by 2020, of which USD 355 million has been realized as of fourth quarter 2018. Yara has identified additional improvement potential and plans to expand both the scope and timeframe of the program during first half 2019. Yara's Board of Directors will propose to the Annual General Meeting a dividend payment of NOK 6.50 per share for 2018. Link to report, presentation and webcast 8 February at 09:30 CET: https://www.yara.com/investor-relations/lates...ly-report/ Contact Thor Giæver, Investor Relations Mobile: (+47) 48 07 53 56 E-mail: thor.giaver@yara.com Kristin Nordal, Media Relations Mobile: (+47) 90 01 55 50 E-mail: kristin.nordal@yara.com About Yara Yara grows knowledge to responsibly feed the world and protect the planet, to fulfill our vision of a collaborative society, a world without hunger and a planet respected. To meet these commitments, we have taken the lead in developing digital farming tools for precision farming and work closely with partners throughout the whole food value chain to develop more climate-friendly crop nutrition solutions. In addition, we are committed to working towards sustainable mineral fertilizer production. We foster an open culture of diversity and inclusion that promotes the safety and integrity of our employees, contractors, business partners, and society at large. Founded in 1905 to solve the emerging famine in Europe, Yara has a worldwide presence with more than 17,000 employees and operations in over 60 countries. In 2018, Yara reported revenues of USD 13.1 billion. www.yara.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachments

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Rollins' Current Market Position and Outlook

Updated Category News Views 226

Analyzing Rollins Inc.'s Stock Performance As we look at the current performance of Rollins Inc. (NYSE: ROL), the shares are trading around $55.73, reflecting a decrease of 1.24% in the recent session. While the stock has dipped by 3.81% over the past month, it has impressively increased by 10.91% year-over-year. This presents a curious juxtaposition of short-term...

Continue Reading
Silver One Reports Major Mineral Resource Estimate for Candelaria

Updated Category News Views 199

Candelaria Project Mineral Resource Estimate Silver One Resources Inc. (OTCQX: SLVRF) has made a significant announcement regarding the completion of a mineral resource estimate for the Candelaria Project. This estimate is prepared in accordance with the National Instrument 43-101, ensuring that the resources are assessed with high standards of transparency and accuracy....

Continue Reading
Investors Alert: Zynex (ZYXI) Faces Serious Legal Scrutiny

Updated Category News Views 197

Legal Investigation into Zynex, Inc. The Law Offices of Frank R. Cruz have announced a crucial investigation regarding Zynex, Inc. (ZYXI) focused on potential violations of federal securities laws. This investigation comes as a response to significant concerns raised about the company's recent financial disclosures and their implications for investors. Understanding the...

Continue Reading
Understanding Rentokil Initial's Stock Valuation Insights

Updated Category News Views 100

Assessing Rentokil Initial's Stock Performance In the current trading session, Rentokil Initial Inc. (NYSE: RTO) shares are priced at $26.42, witnessing a notable increase of 1.46%. Over the past month, the stock has gained 1.40%, though it has faced a decline of 7.78% in the last year. This fluctuation raises questions among shareholders regarding its valuation, despite...

Continue Reading
Innovative Insights on Efzofitimod from aTyr Pharma's Recent Conference

Updated Category News Views 177

aTyr Pharma Highlights Efzofitimod at Key Conference At a significant scientific gathering, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology firm known for its innovative therapeutic approaches, shared compelling data concerning efzofitimod. This presentation underlined important insights about the treatment of pulmonary sarcoidosis. The conference, which...

Continue Reading